Clinical Trials Directory

Trials / Completed

CompletedNCT03158077

Switching Strategy With Raltegravir + ABC / 3TC in Controlled HIV-1 Infection

Switching Strategy With Raltegravir + ABC / 3TC in Controlled HIV-1 Infection: Observational Retrospective Study at 48 Weeks - KIRAL Study

Status
Completed
Phase
Study type
Observational
Enrollment
467 (actual)
Sponsor
Fundacion SEIMC-GESIDA · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Retrospective observational study, multicentric with Spanish hospitals, in which a switching or change strategy with RAL and ABC / 3TC guidelines was used, in the48 weeks before the start of the study, in order to determine parameters of Effectiveness and security.

Detailed description

The study consists of a 4-weeks data recording period, during which the follow-up information recorded by physicians in electronic or paper medical history will be analyzed from patients who opted for a change to that study pattern (RAL and ABC / 3TC).

Conditions

Timeline

Start date
2016-11-15
Primary completion
2017-04-20
Completion
2017-04-20
First posted
2017-05-17
Last updated
2017-05-17

Locations

14 sites across 1 country: Spain

Source: ClinicalTrials.gov record NCT03158077. Inclusion in this directory is not an endorsement.